News
ACHFF
0.405
NaN%
--
Arch Biopartners closes CAD 0.6 million private placement of common shares
Reuters · 5d ago
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 5d ago
Arch Biopartners announces CAD 0.6 million private placement of common shares
Reuters · 03/30 10:04
ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT
Reuters · 03/30 10:03
Arch Biopartners signs clinical trial agreement with Fraser Health Authority for Phase II LSALT peptide trial
Reuters · 03/24 13:13
ARCH BIOPARTNERS AND THE FRASER HEALTH AUTHORITY ENTER INTO A CLINICAL TRIAL AGREEMENT FOR THE PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 03/24 13:13
St. Michael’s Hospital begins dosing patients in Arch Biopartners’ 240-patient Phase II LSALT peptide trial
Reuters · 03/20 11:17
ARCH BIOPARTNERS ANNOUNCES ST. MICHAEL’S HOSPITAL COMMENCES PATIENT DOSING IN THE PHASE II CS-AKI TRIAL OF LSALT PEPTIDE
Reuters · 03/20 11:05
Arch Biopartners’ Q1 net loss widens to CAD 1.6 million (3.7x)
Reuters · 03/03 03:01
Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD
TipRanks · 02/09 12:45
Arch Biopartners Advances IL-32 Drug Candidate Toward Clinical Trials for Diabetic Kidney Disease
Reuters · 02/09 12:29
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Barchart · 02/09 06:28
Arch Biopartners posts FY net loss of USD 1.6 million and cash flow from financing activities of USD 1.6 million
Reuters · 01/29 05:10
Arch Biopartners Appoints Dr. Patrick Vink as Chairman of the Board
Reuters · 01/16 13:15
ARCH BIOPARTNERS ANNOUNCES APPOINTMENT OF DR. PATRICK VINK AS CHAIRMAN OF THE BOARD
Reuters · 01/16 13:15
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16/2025 12:45
Arch Biopartners Wins Ethics Approval for Phase II Cardiac Surgery-Associated AKI Trial at St. Michael’s Hospital
Reuters · 12/16/2025 12:40
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Barchart · 12/16/2025 06:40
Arch Biopartners Raises $600,000 in Private Placement of Common Shares
Reuters · 11/19/2025 21:34
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 11/19/2025 21:27
More
Webull provides a variety of real-time ACHFF stock news. You can receive the latest news about Arch Biopartners through multiple platforms. This information may help you make smarter investment decisions.
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.